MUNDIPHARMA
16.4.2024 11:01:35 CEST | Business Wire | Press release
Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/
The product is an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3
It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1
Work is already under way to source an alternative to the HFA-227 gas used in fluticasone propionate/formoterol fumarate pMDI. This new collaboration will revitalise the efforts to identify and switch to a more environmentally friendly propellant. If successful, this will result in a significantly lower impact on global warming and alignment with European Union regulation on fluorinated greenhouse gases.1
With more than 262 million people living with asthma globally, the reformulation of some asthma treatments to reduce carbon emissions could have a significant impact on the global carbon footprint.4,5
“We are dedicated to positively influencing the life of asthma patients across the globe. This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler. We are determined to achieve this before the European Union ban of HFA (hydrofluoroalkane) gases comes into effect, and our collaboration with Vectura demonstrates this, as well as our aim to an overall commitment to sustainable healthcare innovation,” said Yuri Martina, Chief Development and Medical Officer at Mundipharma.
“At Vectura, our priority is to ensure that patients prescribed fluticasone propionate/formoterol fumarate pMDI can continue to have access to this treatment. Using Vectura’s expertise and extensive track record in the development of inhaled prescription medicines and devices, we believe the collaboration with Mundipharma will enable us to meet our environmental responsibilities and enable patients to use fluticasone propionate/formoterol fumarate pMDI in the years to come,” said Geraldine Venthoye, Chief Scientific Officer, Vectura.
®: FLUTIFORM is a registered trademark of Jagotec AG used under licence by Mundipharma.
References
- Regulation (EU) No 517/2014 of the European Parliament and of the Council of 16 April 2014 on fluorinated greenhouse gases and repealing Regulation (EC) No 842/2006 Text with EEA relevance. Available at: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=uriserv:OJ.L_.2014.150.01.0195.01.ENG (last accessed March 2024)
- flutiform® pMDI emissions manufacturing data, Q4 2022 – Q4 2023. Data on file.
- flutiform® Summary of Product Characteristics (SmPC). Last updated 13 April 2022. https://www.emcpi.com/pi/26954. (last accessed April 2024).
- Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22
- NHS England, World Asthma Day: tackling climate change and improving respiratory care. Available at https://www.england.nhs.uk/blog/world-asthma-day-tackling-climate-change-and-improving-respiratory-care/ (last accessed March 2024)
*ENDS*
Job code: SciA-FLU-2400001| Date of preparation: April 2024
|
Notes to Editors
About flutiform® (fluticasone propionate/formoterol fumarate):
flutiform® is an inhaler (a pressurised metered-dose inhalation, suspension) which contains two active ingredients, fluticasone propionate and formoterol fumarate dihydrate.3 This fixed-dose combination of fluticasone propionate and formoterol fumarate (flutiform®) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β₂ agonist) is appropriate for the management of asthma symptoms.3
About Mundipharma:
Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of respiratory, pain management, infectious disease as well as other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit www.mundipharma.com.
About Vectura:
Vectura is a specialist inhalation contract development and manufacturing organization (CDMO) that provides inhaled drug development solutions to help customers bring their medicines to patients. With 25 years’ experience, it provides a combination of formulation science, device technology, and inhaled development expertise. Vectura is a member of the Vectura Fertin Pharma group of companies. For more information visit www.vectura.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416962162/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Named to the CNBC World's Top Fintech Companies 2026 List23.7.2026 14:00:00 CEST | Press release
Payment category recognition marks Riskified's continued presence among the world's leading fintech innovators Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, has been named to CNBC's World's Top Fintech Companies 2026 list, in the Payments category. The list, now in its fourth edition, is produced by CNBC in partnership with Statista Inc., the global statistics and industry ranking firm. It was announced on July 22, 2026, and is available on CNBC's website. This is Riskified's second time making the list. The company previously earned this recognition in 2024, reinforcing its position in the ecommerce fraud and risk intelligence sector and underscoring its ongoing success in empowering businesses to grow revenue and profitability by mitigating risk through its AI-powered platform. CNBC and Statista's ranking covers the top 500 companies across eight fintech segments — Payments, Neobanking, Alternative Financing, Wealth Technology, Digital As
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 13:00:00 CEST | Press release
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustatRecruitment completed in Phase 3 registrational study in patients with late-infantile and juvenile GM1/GM2 gangliosidosesEnrollment in Niemann-Pick type C disease (NPC) Phase 3 study is ongoingTopline data from GM1/GM2 gangliosidoses Phase 3 study is anticipated in early 2028 Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, invest
Francisco Partners Closes $21 Billion Across Flagship and Agility Funds23.7.2026 13:00:00 CEST | Press release
Largest fundraise in the firm’s history brings total capital raised to more than $75 billion Francisco Partners (“FP”), a leading global investment firm that specializes in partnering with technology companies, today announced the closing of $21 billion in capital commitments across its Francisco Partners VIII, L.P. flagship fund and Francisco Partners Agility IV, L.P., its middle-market fund. FP exceeded its initial targets of $14.0 billion and $3.5 billion, respectively. This milestone builds on Francisco Partners' longstanding track record of performance, underscored by its distinction as the only firm to rank among the top three performers in each of the past six HEC-Dow Jones Large Buyout Performance Rankings.* “In our business, long-term success is created through a series of relationships built on years of trust and collaboration," said Dipanjan (“DJ”) Deb, Co-Founder and CEO of Francisco Partners. "We want to thank our investors for their support, our management teams for their
Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days23.7.2026 10:21:00 CEST | Press release
The Prague Folklore Days 2026 was held on July 17 and 18 in the heart of Prague, bringing together 56 international arts groups from Germany, Austria, Slovakia, Spain, the Netherlands, and Poland. Four Taiwanese groups took part: Hildebrand Yu’s ocarina band, the Shi-xian Huqin Orchestra, the Taipei Folk Orchestra, and the Four Strings Ensemble. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722841530/en/ Taiwanese ensembles showcase erhu and ocarina at Prague Folklore Days Led by Huang Chun-sin, the official Taiwan representative band featured a diverse lineup of ocarina, erhu, and dance performers. Their program stood out among the European groups with its distinctive character and vivid stage presence. Hildebrand Yu’s ocarina band captivated audiences with warm, uplifting melodies accompanied by the ocarina and ukulele. Yu also performed “Twilight Waltz,” delivering a heartfelt piece of poetic expression, like sunlight
Taiwan Children’s Choirs Garner Major Awards at Hungarian Choral Competition23.7.2026 09:33:00 CEST | Press release
Competing against 36 leading contenders from 20 countries, four Taiwanese children’s choirs have garnered several major awards and top honors at the 5th Budapest International Choral Celebration, showcasing Taiwan’s cultural diversity and music excellence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722613876/en/ Puzangalan Children’s Choir and Yo Wu Wei Children’s Chorus join forces with international choral ensembles and orchestras to perform Mozart’s Requiem Mass in D minor, K. 626 at the Béla Bartók National Concert Hall of Müpa Budapest. With its pure, angelic voices and exceptional vocal techniques, Puzangalan Children’s Choir from Pingtung County won the top prize, Laurea Summa Cum Laude, in the Grand Prix Competition’s Youth Choir of Equal Voices, Folklore, and Sacred Music categories. In the Open Competition, Yo Wu Wei Children’s Chorus claimed three gold prizes in the categories of Youth Choir of Equal Voices
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom